AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,754.00p
   
  • Change Today:
    -46.00p
  • 52 Week High: 11,054.00
  • 52 Week Low: 8,063.00
  • Currency: UK Pounds
  • Shares Issued: 1,549.48m
  • Volume: 2,073,571
  • Market Cap: £166,631m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.2% 2.2%
Div Cover 0.0 2.3
Op Mrgn 2.8% 29.0%
ROCE 0.0%  
Latest F'cast
P/E 1619.2 19.8
PEG n/a n/a
Pr/Revenue 5364.3 4.7
Pr/Book 5.1  
Latest F'cast
Revenue 40.6% 78280.0%
PBT n/a n/a
EPS -96.7% 8234.4%
DPS 2.5% -30.6%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 22,465.00 2,227.00 428.00¢ 14.5 n/a -1% 280.00¢ 4.5%
31-Dec-18 22,090.00 1,993.00 170.00¢ 41.8 n/a -60% 280.00¢ 3.9%
31-Dec-19 24,384.00 1,548.00 103.00¢ 89.3 n/a -39% 280.00¢ 3.0%
31-Dec-20 26.62 3.92 244.00¢ 36.3 0.3 +137% 280.00¢ 3.2%
31-Dec-21 37.42 (0.26) 8.00¢ 1,312.1 n/a -97% 287.00¢ 2.7%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 35,473.88 10,289.28 542.47p 19.8 0.0 +8,234% 240.95p 2.2%
31-Dec-23 37,986.25 12,089.32 635.39p 16.9 1.0 +17% 253.76p 2.4%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Total Voting Rights 01-Jul-2022 15:00 RNS
Imfinzi improved pCR in resectable lung cancer 30-Jun-2022 07:00 RNS
Enhertu recommended for breast cancer EU approval 27-Jun-2022 07:05 RNS

AstraZeneca ShareCast News

Covid-19 cases surge during latest week due to B... 01-Jul-2022 ShareCast
Oxford Biomedica signs new Covid vaccine deal wi... 01-Jul-2022 ShareCast
AstraZeneca receives positive interim results fr... 30-Jun-2022 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,754.00p
Change Today -46.00p
% Change -0.43 %
52 Week High 11,054.00
52 Week Low 8,063.00
Volume 2,073,571
Shares Issued 1,549.48m
Market Cap £166,631m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
78.06% below the market average78.06% below the market average78.06% below the market average78.06% below the market average78.06% below the market average
34.55% above the sector average34.55% above the sector average34.55% above the sector average34.55% above the sector average34.55% above the sector average
Price Trend
86.35% above the market average86.35% above the market average86.35% above the market average86.35% above the market average86.35% above the market average
93.65% above the sector average93.65% above the sector average93.65% above the sector average93.65% above the sector average93.65% above the sector average
Income
97.24% below the market average97.24% below the market average97.24% below the market average97.24% below the market average97.24% below the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average
Growth
81.69% below the market average81.69% below the market average81.69% below the market average81.69% below the market average81.69% below the market average
95% below the sector average95% below the sector average95% below the sector average95% below the sector average95% below the sector average

What The Brokers Say

Strong Buy 22
Buy 2
Neutral 5
Sell 0
Strong Sell 0
Total 29
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 24-Feb-22 12-Aug-21
Paid 28-Mar-22 13-Sep-21
Amount 197.00¢ 90.00¢

Trades for 01-Jul-2022

Time Volume / Share Price
16:45 58 @ 10,728.00p
16:45 58 @ 10,728.00p
16:39 2 @ 10,754.00p
16:35 625,247 @ 10,754.00p
16:32 4,182 @ 10,693.86p

Top of Page